Journal
TARGETED ONCOLOGY
Volume 5, Issue 3, Pages 217-227Publisher
SPRINGER
DOI: 10.1007/s11523-010-0151-8
Keywords
Glioma cancer stem cells; STAT3; Glioblastoma multiforme; Immunotherapy
Categories
Funding
- Anthony Bullock III Foundation
- Dr. Marnie Rose Foundation
- Mitchell Foundation
- University of Texas M. D. Anderson Cancer Center
- National Institutes of Health [CA120813]
Ask authors/readers for more resources
Glioblastoma multiforme (GBM) is a lethal cancer that responds poorly to radiotherapy and chemotherapy. Glioma cancer stem cells (gCSCs) have been shown to recapitulate the characteristic features of GBM and to mediate chemotherapy and radiation resistance. Immunotherapeutic targeting of this cell population holds therapeutic promise but must be considered in the context of the immunosuppressive properties mediated by the gCSC. Recent findings have indicated that this goal will be challenging because the gCSC can suppress both the innate and adaptive immune systems by a variety of gCSC-secreted products and cell-membrane interactions. In this review article, we will attempt to reconcile the disparate research findings regarding the potential of immune targeting of the gCSC and propose several novel solutions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available